NEJM: Pirtobrutinib is effective in CLL patients who have received prior BTK inhibitor therapy.

Published Date: 10 Jul 2023

A highly selective noncovalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor called pirtobrutinib has demonstrated promise in a recent clinical trial.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Can Children With Low-Risk Hodgkin Lymphoma Skip Radiation?

2.

The need for more Latinx participants in Alzheimer's trials is urgent.

3.

Admissions, medical colleges, fees, and eligibility requirements information for the DNB Post Diploma in Radiation Oncology.

4.

Study identifies new approach to protect the brain during radiation therapy

5.

Study Supports Lactated Ringer Solution for Fluid Resuscitation in SCD


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot